drugset / Trial / NCT03062280

A Study of the Efficacy, Safety and Tolerability of Chronocort in Treating CAH

NCT03062280

Phase 3 Completed 91 enrolled Neurocrine UK Limited
NaSingle-groupOpen-labelTreatment

Summary

Subjects completing study DIUR-005 and those who have already completed study DIUR-003 will be offered the opportunity either to continue Chronocort® therapy or to switch from their current glucocorticoid therapy to Chronocort® in this open-label study.

Timeline

Start
2016-08-18
Primary completion
2022-07-13
Completion
2022-07-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydrocortisone Other / unclassified